Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

MEK is a canonical effector of mutant KRAS; however, MEK inhibitors fail to yield satisfactory clinical outcomes in KRAS-mutant cancers. Here, we identified mitochondrial oxidative phosphorylation (OXPHOS) induction as a profound metabolic alteration to confer KRAS-mutant non-small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Juanjuan, Lian, Zhengke, Xia, Xinting, Lu, Yue, Hu, Kewen, Zhang, Yunpeng, Liu, Yanan, Hu, Longmiao, Yuan, Kun, Sun, Zhenliang, Pang, Xiufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031260/
https://www.ncbi.nlm.nih.gov/pubmed/36970205
http://dx.doi.org/10.1016/j.apsb.2022.10.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031260/
https://www.ncbi.nlm.nih.gov/pubmed/36970205
http://dx.doi.org/10.1016/j.apsb.2022.10.023

Ejemplares similares